Long-Term Outcomes of Venous Resections in Pancreatic Ductal Adenocarcinoma Patients

医学 危险系数 比例危险模型 胰腺癌 肠系膜上静脉 混淆 腺癌 剖腹探查术 胃肠病学 内科学 外科 癌症 门静脉 置信区间
作者
Martin Sillesen,Carsten Palnæs Hansen,Emilie Even Dencker,Stefan Kobbelgaard Burgdorf,Paul Suno Krohn,Mogens Tornby Stender,Claus Wilki Fristrup,Jan Henrik Storkholm
出处
期刊:Annals of surgery open [Wolters Kluwer]
卷期号:3 (4): e219-e219 被引量:1
标识
DOI:10.1097/as9.0000000000000219
摘要

To investigate whether pancreatic resections (PR) for pancreatic ductal adenocarcinoma (PDAC) is associated with worse survival when resection of the superior mesenteric vein/portal vein (SMV/PV) is required.PR for PDAC with resection of the superior mesenteric vein/portal vein (SMV/PV, PR+V resection) may be associated with inferior overall survival (OS) compared with PR without the need for SMV/PV resection (PR-V). We hypothesized that PR+V results in lower OS compared with PR-V.Retrospective study using data from the nationwide Danish Pancreatic Cancer Database from 2011 to 2020. Data on patients who underwent PR for PDAC were extracted. A group of PR patients found nonresectable on exploratory laparotomy (EXP) was also included. OS was assessed using Kaplan-Meier and Cox proportional hazards models adjusting for confounders (age, sex, R-resection level, chemotherapy, comorbidities, histology T and N classification, procedure subtype as well as tumor distance to the SMV/PV).Overall, 2403 patients were identified. Six hundred two underwent exploration only (EXP group), whereas 412 underwent pancreatic resection with (PR+V group) and 1389 (PR-V) without SMV/PV resection. Five-year OS for the PR+V group was lower (20% vs 30%) compared with PR-V, although multivariate Cox proportional hazards modeling could not associate PR+V status with OS (Hazard ratio 1.11, P = 0.408).When correcting for confounders, PR+V was not associated with lower OS compared with PR-V.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
iaskwho发布了新的文献求助10
1秒前
111完成签到,获得积分10
2秒前
2秒前
DarrenVan完成签到,获得积分10
5秒前
英俊的铭应助lk采纳,获得10
5秒前
lucky完成签到 ,获得积分10
5秒前
王国科发布了新的文献求助10
6秒前
高高的天亦完成签到 ,获得积分10
6秒前
小D发布了新的文献求助10
7秒前
村上春树的摩的完成签到 ,获得积分10
7秒前
Fox完成签到,获得积分20
8秒前
9秒前
一一完成签到 ,获得积分10
9秒前
10秒前
ccm应助科研通管家采纳,获得10
11秒前
Bio应助科研通管家采纳,获得150
11秒前
无花果应助科研通管家采纳,获得10
11秒前
英姑应助科研通管家采纳,获得10
11秒前
12秒前
ccm应助科研通管家采纳,获得10
12秒前
科目三应助科研通管家采纳,获得10
12秒前
若ruofeng应助科研通管家采纳,获得20
12秒前
dew应助科研通管家采纳,获得10
12秒前
12秒前
若ruofeng应助科研通管家采纳,获得20
12秒前
馆长应助科研通管家采纳,获得10
12秒前
小二郎应助科研通管家采纳,获得10
12秒前
若ruofeng应助科研通管家采纳,获得20
12秒前
若ruofeng应助科研通管家采纳,获得20
12秒前
若ruofeng应助科研通管家采纳,获得20
12秒前
12秒前
若ruofeng应助科研通管家采纳,获得20
12秒前
若ruofeng应助科研通管家采纳,获得20
12秒前
若ruofeng应助科研通管家采纳,获得20
12秒前
今后应助科研通管家采纳,获得10
12秒前
orixero应助科研通管家采纳,获得10
12秒前
科研通AI2S应助科研通管家采纳,获得10
12秒前
科研通AI6应助科研通管家采纳,获得10
12秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5142180
求助须知:如何正确求助?哪些是违规求助? 4340425
关于积分的说明 13517521
捐赠科研通 4180348
什么是DOI,文献DOI怎么找? 2292405
邀请新用户注册赠送积分活动 1293003
关于科研通互助平台的介绍 1235514